{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:09:47Z","timestamp":1792789787708,"version":"4.5.0"},"reference-count":121,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","award":["32154\/9"],"award-info":[{"award-number":["32154\/9"]}],"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"crossref"}]},{"award":["32154\/9"],"award-info":[{"award-number":["32154\/9"]}],"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Classical Hodgkin lymphoma (cHL) is distinguished by a rare population of Hodgkin and Reed\u2013Sternberg (HRS) cells that has largely extinguished its germinal center (GC) B-cell identity while maintaining survival, immune escape, and dependence on a highly organized tumor microenvironment (TME). This narrative review examines how interacting epigenetic mechanisms construct and stabilize this malignant state and evaluates whether it can be therapeutically reprogrammed. The relevant mechanistic and clinical literature available through 2026 was synthesized, encompassing lineage factor disruption, DNA methylation, histone modifications, Polycomb repression, chromatin-remodeling lesions, non-coding RNAs, antigen presentation, immune checkpoint regulation, and epigenetic therapies in cHL. Lineage erasure appears to be an actively maintained program produced by promoter hypermethylation, histone deacetylation, Polycomb-associated repression, altered histone demethylase activity, transcription factor antagonism, and somatic lesions affecting chromatin regulators. These mechanisms coexist with structural and transcriptional alterations involving antigen presentation and programmed death ligand 1\/programmed death ligand 2 (PD-L1\/PD-L2), while non-coding RNAs and extracellular vesicles provide an additional regulatory layer connecting HRS cells with immune and stromal components of the TME. Epigenetic repression is heterogeneous in its reversibility: partially methylated or deacetylated loci may remain pharmacologically responsive, whereas densely methylated, Polycomb-associated, or genetically entrenched states are less likely to be restored through isolated interventions. Histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors can nevertheless alter tumor- and immune-related programs, supporting combinations with PD-1 blockade. Complete restoration of a physiological B-cell epigenome is unlikely; however, the HRS state remains therapeutically modifiable. Epigenetic therapy may therefore be most effective when used to reduce state stability and increase immune visibility rather than to achieve complete lineage reconstitution.<\/jats:p>","DOI":"10.3390\/medicina62091740","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:56Z","timestamp":1788966116000},"page":"1740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Epigenetic Architecture of Classical Hodgkin Lymphoma: Lineage Erasure, Immune Escape, and Therapeutic Reprogramming"],"prefix":"10.3390","volume":"62","author":[{"given":"Matei","family":"Seleusan","sequence":"first","affiliation":[{"name":"Department of Personalised Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cenariu","sequence":"additional","affiliation":[{"name":"Department of Personalised Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9397-0791","authenticated-orcid":false,"given":"Adrian-Bogdan","family":"\u021aigu","sequence":"additional","affiliation":[{"name":"Department of Personalised Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[{"name":"Department of Personalised Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-6911","authenticated-orcid":false,"given":"M\u0103d\u0103lina","family":"Nistor","sequence":"additional","affiliation":[{"name":"Department of Personalised Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-0018","authenticated-orcid":false,"given":"Ximena Maria","family":"Muresan","sequence":"additional","affiliation":[{"name":"Department of Personalised Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9461-987X","authenticated-orcid":false,"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[{"name":"Department of Haematology, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Haematology, Ion Chiricu\u021b\u0103 Oncology Institute, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Kuppers","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molmed.2024.10.004","article-title":"Advances in Hodgkin lymphoma research","volume":"31","author":"Kuppers","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2005-09-3765","article-title":"Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma","volume":"107","author":"Ushmorov","year":"2006","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3324\/haematol.2010.031138","article-title":"Classical Hodgkin\u2019s lymphoma shows epigenetic features of abortive plasma cell differentiation","volume":"96","author":"Seitz","year":"2011","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/leu.2008.12","article-title":"Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype","volume":"22","author":"Ehlers","year":"2008","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","author":"Rui","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal Centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: Role in B-cell physiology and malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bienz, M., Ramdani, S., and Knecht, H. (2020). Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186623"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1182\/blood-2005-06-2341","article-title":"Rescue of \u201ccrippled\u201d germinal center B cells from apoptosis by Epstein-Barr virus","volume":"106","author":"Mancao","year":"2005","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1182\/blood-2005-06-2327","article-title":"Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes","volume":"106","author":"Chaganti","year":"2005","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/PAS.0000000000001180","article-title":"Utility of Combined EZH2, p-ERK1\/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas","volume":"43","author":"Tian","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni1285","article-title":"Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma","volume":"7","author":"Mathas","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/leu.2013.211","article-title":"PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma","volume":"28","author":"Dimitrova","year":"2014","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4161\/cc.5.10.2737","article-title":"Reprogramming of B lymphoid cells in human lymphoma pathogenesis","volume":"5","author":"Janz","year":"2006","journal-title":"Cell Cycle"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/modpathol.3800577","article-title":"Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays","volume":"19","author":"Sanchez","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/path.1661","article-title":"Abnormal PcG protein expression in Hodgkin\u2019s lymphoma. Relation with E2F6 and NFkappaB transcription factors","volume":"204","author":"Sanchez","year":"2004","journal-title":"J. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-12-256446","article-title":"KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma","volume":"116","author":"Guan","year":"2010","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1038\/sj.emboj.7601824","article-title":"The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation","volume":"26","author":"Feinberg","year":"2007","journal-title":"EMBO J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3324\/haematol.2012.061770","article-title":"ETS1 encoding a transcription factor involved in B-cell differentiation is recurrently deleted and down-regulated in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Overbeck","year":"2012","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1038\/s41467-023-41954-8","article-title":"Transcriptional reprogramming by mutated IRF4 in lymphoma","volume":"14","author":"Schleussner","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/modpathol.2009.54","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: Distinctive tumor and microenvironment markers","volume":"22","author":"Salcedo","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1182\/blood-2003-04-1197","article-title":"Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression","volume":"104","author":"Ushmorov","year":"2004","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1038\/sj.onc.1205629","article-title":"Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin\/Reed-Sternberg cells of classical Hodgkin lymphoma","volume":"21","author":"Hertel","year":"2002","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jmb.2005.05.032","article-title":"Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines","volume":"350","author":"Doerr","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2011.194","article-title":"Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes","volume":"26","author":"Ammerpohl","year":"2012","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin\u2019s lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2353\/ajpath.2008.070294","article-title":"Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling","volume":"172","author":"Akimzhanov","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00441-014-1896-7","article-title":"The role of 5-hydroxymethylcytosine in human cancer","volume":"356","author":"Pfeifer","year":"2014","journal-title":"Cell Tissue Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/onc.2012.67","article-title":"Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation","volume":"32","author":"Yang","year":"2013","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106408","DOI":"10.1016\/j.leukres.2020.106408","article-title":"Diminished expression of 5hmc in Reed-Sternberg cells in classical Hodgkin lymphoma is a common epigenetic marker","volume":"96","author":"Siref","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41422-021-00606-6","article-title":"Mechanisms of Polycomb group protein function in cancer","volume":"32","author":"Parreno","year":"2022","journal-title":"Cell Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.molcel.2012.01.002","article-title":"PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes","volume":"45","author":"Gao","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"zcab039","DOI":"10.1093\/narcan\/zcab039","article-title":"Polycomb group proteins in cancer: Multifaceted functions and strategies for modulation","volume":"3","author":"Wang","year":"2021","journal-title":"NAR Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0002-9440(10)64583-X","article-title":"Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin\u2019s disease","volume":"157","author":"Raaphorst","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0002-9440(10)63175-6","article-title":"Unique polycomb gene expression pattern in Hodgkin\u2019s lymphoma and Hodgkin\u2019s lymphoma-derived cell lines","volume":"164","author":"Dukers","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.onc.1201262","article-title":"Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger","volume":"15","author":"Alkema","year":"1997","journal-title":"Oncogene"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1101\/gad.13.20.2678","article-title":"Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a\/ARF","volume":"13","author":"Jacobs","year":"1999","journal-title":"Genes Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/16476","article-title":"The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus","volume":"397","author":"Jacobs","year":"1999","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1242\/dev.128.9.1587","article-title":"Mice doubly deficient for the Polycomb Group genes Mel18 and Bmi1 reveal synergy and requirement for maintenance but not initiation of Hox gene expression","volume":"128","author":"Akasaka","year":"2001","journal-title":"Development"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., and Giorgi, F.M. (2020). Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes, 11.","DOI":"10.3390\/genes11050556"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: Implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10637-010-9588-y","article-title":"Histone deacetylase inhibitors in Hodgkin lymphoma","volume":"28","author":"Buglio","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1182\/blood.V110.11.2566.2566","article-title":"Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL)","volume":"110","author":"Younes","year":"2007","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2009.07887.x","article-title":"Expression of histone deacetylases in lymphoma: Implication for the development of selective inhibitors","volume":"147","author":"Gloghini","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/14728221003796609","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin\u2019s lymphoma","volume":"14","author":"Adams","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/CAD.0000000000000610","article-title":"Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma","volume":"29","author":"Huang","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/onc.2010.579","article-title":"The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin\u2019s Lymphoma","volume":"30","author":"Anderton","year":"2011","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1038\/emboj.2009.271","article-title":"Jmjd3 contributes to the control of gene expression in LPS-activated macrophages","volume":"28","author":"Narang","year":"2009","journal-title":"EMBO J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.21873\/anticanres.11020","article-title":"Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma","volume":"36","author":"Bur","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.1454","article-title":"Inactivating I kappa B epsilon mutations in Hodgkin\/Reed-Sternberg cells","volume":"201","author":"Emmerich","year":"2003","journal-title":"J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cancergencyto.2009.11.005","article-title":"Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma","volume":"197","author":"Liu","year":"2010","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-019-0195-7","article-title":"Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: Mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma","volume":"9","author":"Mata","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","article-title":"Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth","volume":"114","author":"Hashwah","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3324\/haematol.12875","article-title":"Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin\u2019s lymphoma by array-based comparative genomic hybridization","volume":"93","author":"Hartmann","year":"2008","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Santisteban-Espejo, A., Bernal-Florindo, I., Montero-Pavon, P., Perez-Requena, J., Atienza-Cuevas, L., Fernandez-Valle, M.D.C., Villalba-Fernandez, A., and Garcia-Rojo, M. (2024). Pathogenic Variants Associated with Epigenetic Control and the NOTCH Pathway Are Frequent in Classic Hodgkin Lymphoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052457"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ncb3597","article-title":"Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors","volume":"19","author":"Horton","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1126\/science.aam7304","article-title":"The cancer epigenome: Concepts, challenges, and therapeutic opportunities","volume":"355","author":"Dawson","year":"2017","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin Lymphoma with Reduced beta2M\/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imm.12136","article-title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma","volume":"140","author":"Cycon","year":"2013","journal-title":"Immunology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin\u2019s lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/ijc.29934","article-title":"Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation","volume":"138","author":"Birkenmeier","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","article-title":"PD-L1\/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma","volume":"34","author":"Kawashima","year":"2020","journal-title":"Leukemia"},{"key":"ref_85","first-page":"3827","article-title":"MGCD0103 induces apoptosis and simultaneously increases the expression of NF-kappaB and PD-L1 in classical Hodgkin\u2019s lymphoma","volume":"16","author":"Huang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pan, Y., Cengiz, R., Kluiver, J., Diepstra, A., and Van den Berg, A. (2024). Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis. Cancers, 16.","DOI":"10.3390\/cancers16061126"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Cordeiro, A., Monzo, M., and Navarro, A. (2017). Non-Coding RNAs in Hodgkin Lymphoma. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061154"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1126\/science.1091903","article-title":"MicroRNAs modulate hematopoietic lineage differentiation","volume":"303","author":"Chen","year":"2004","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1073\/pnas.0404432101","article-title":"MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/gcc.10186","article-title":"High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma","volume":"37","author":"Kroesen","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/path.1825","article-title":"BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas","volume":"207","author":"Kluiver","year":"2005","journal-title":"J. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.1096781","article-title":"Identification of virus-encoded microRNAs","volume":"304","author":"Pfeffer","year":"2004","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C., and Marks, D.S. (2004). Human MicroRNA targets. PLoS Biol., 2.","DOI":"10.1371\/journal.pbio.0020363"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1002\/j.1460-2075.1996.tb00949.x","article-title":"Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities","volume":"15","author":"McKercher","year":"1996","journal-title":"EMBO J."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Paczkowska, J., Janiszewska, J., Bein, J., Schneider, M., Bednarek, K., Ustaszewski, A., Hartmann, S., Hansmann, M.L., and Giefing, M. (2020). The Tumor Suppressive mir-148a Is Epigenetically Inactivated in Classical Hodgkin Lymphoma. Cells, 9.","DOI":"10.3390\/cells9102292"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1038\/onc.2015.6","article-title":"Regulatory circuit of PKM2\/NF-kappaB\/miR-148a\/152-modulated tumor angiogenesis and cancer progression","volume":"34","author":"Xu","year":"2015","journal-title":"Oncogene"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.18632\/oncotarget.2390","article-title":"Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin\u2019s lymphomas","volume":"5","author":"Yim","year":"2014","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ajpath.2017.02.016","article-title":"miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis","volume":"187","author":"Yuan","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.ajpath.2016.05.011","article-title":"Long Noncoding RNA Expression Profiling in Normal B-Cell Subsets and Hodgkin Lymphoma Reveals Hodgkin and Reed-Sternberg Cell-Specific Long Noncoding RNAs","volume":"186","author":"Tayari","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e89631","DOI":"10.1172\/jci.insight.89631","article-title":"Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients","volume":"1","author":"Zijlstra","year":"2016","journal-title":"JCI Insight"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e12121","DOI":"10.1002\/jev2.12121","article-title":"Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma","volume":"10","author":"Drees","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Salzmann, R.J.S., Garbin, A., Gaffo, E., Elia, C., Martire, G., Bortoluzzi, S., Tondo, A., Muggeo, P., Sala, A., and Pizzi, M. (2024). Extracellular Vesicle miR-122-5p as a Prognostic Biomarker in Pediatric Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413243"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Dorsam, B., Bosl, T., Reiners, K.S., Barnert, S., Schubert, R., Shatnyeva, O., Zigrino, P., Engert, A., Hansen, H.P., and von Strandmann, E.P. (2018). Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01358"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/path.4306","article-title":"Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin\u2019s lymphoma","volume":"232","author":"Hansen","year":"2014","journal-title":"J. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1182\/blood-2017-07-794529","article-title":"Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma","volume":"131","author":"Higuchi","year":"2018","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: Results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: An open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","article-title":"Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines","volume":"112","author":"Buglio","year":"2008","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2010.08342.x","article-title":"The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism","volume":"151","author":"Buglio","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","article-title":"HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma","volume":"117","author":"Buglio","year":"2011","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2016.142406","article-title":"ENGAGE- 501: Phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma","volume":"101","author":"Batlevi","year":"2016","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1038\/bcj.2014.58","article-title":"Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression","volume":"4","author":"Oki","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.exphem.2011.07.002","article-title":"The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors","volume":"39","author":"Jona","year":"2011","journal-title":"Exp. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","article-title":"Entinostat for treatment of solid tumors and hematologic malignancies","volume":"20","author":"Knipstein","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrg2651","article-title":"Rethinking how DNA methylation patterns are maintained","volume":"10","author":"Jones","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e002347","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:40:58Z","timestamp":1789569658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":121,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091740"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091740","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}